Rousselot Biomedical to Present New Study on X-Pure at CPhI Worldwide 2019
Principal scientist and R&D project manager at Rousselot, Jos Olijve, will discuss the details of the study at the “Influence of Endotoxin on Cellular Activity” conference on day two of CPhI Worldwide from 3:20 pm to 3:50 pm in the Portalhaus, Transparenz 1 room.
Rousselot Biomedical, a collagen-based solutions manufacturer headquartered in The Netherlands, announced it will present the results of a recent study of its endotoxin-purified gelatin, X-Pure, at CPhI Worldwide on Nov. 5–7, 2019 in Frankfurt, Germany.
According to an Oct. 17, 2019 press release, the Rousselot Expertise Center and UMC Utrecht, a university hospital located in The Netherlands, conducted a study on the role of endotoxins in gelatin on mesenchymal stem cells and peripheral blood mononuclear cells and their influence on cellular activity. The teams came to the conclusion that Rousselot’s X-Pure provided a superior environment for stem cell viability and differentiation.
Principal scientist and R&D project manager at Rousselot, Jos Olijve, will discuss the details of the study at the “Influence of Endotoxin on Cellular Activity” conference on day two of CPhI Worldwide from 3:20 pm to 3:50 pm in the Portalhaus, Transparenz 1 room.
Rousselot Biomedical will also be showcasing at booth 120D21 at the event.
Source: Rousselot Biomedical
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
